Zacks.com on MSN14h
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered ...
Merck on Track for Lowest Close Since September 2022 — Data Talk
--Traded as low as $85.73; lowest intraday level since Sept. 27, 2022, when it hit $85.67 These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or ...
One 'Safer' Buy In 10 February Dogs Of The Dow
Verizon's dividend yield and Merck’s growth lead the Dow Dogs. Read why they’re set for solid returns, with other top picks ...
kalkinemedia5d
How Is Merck & Co. (NYSE:MRK) Adapting to Industry Challenges
Highlights,Citigroup revised its price target for Merck & Co., adjusting it from $125 to $115 while maintaining an optimistic ...
Zacks.com on MSN6d
AZN Q4 Earnings Lag, Sales Beat, Stock Up on China Probe Update
AstraZeneca’s AZN fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus ...